Samsung Built a Motion Sickness App for Galaxy Buds, but You Can Try It on Any Earbuds

Why It Matters

Hearapy introduces a software‑only remedy for motion sickness, expanding earbud functionality and giving Samsung a differentiating health‑tech feature across devices.

Key Takeaways

• Hearapy emits 100 Hz sine waves for 60 seconds.
• Works with any earbuds capable of 100 Hz playback.
• Claims up to two hours of motion‑sickness relief.
• Backed by Nagoya University research on balance stimulation.
• Available free on Google Play, not limited to Galaxy Buds.

Pulse Analysis

Motion sickness has long been tackled with visual tricks, medication, or specialized hardware. Hearapy flips the script by using low‑frequency audio to engage the vestibular system, a method supported by Nagoya University’s findings that a minute of 100 Hz tone can improve balance. This auditory approach sidesteps side effects of drugs and offers a discreet, on‑the‑go solution that fits into everyday listening habits, making it attractive to commuters, gamers, and travelers alike.

The app’s hardware‑agnostic design is a strategic move in a crowded earbud market. By requiring only a 100 Hz low‑end capability—common in mid‑range and premium models—Samsung ensures Hearapy can reach users beyond its own Galaxy line. This cross‑compatibility not only broadens the potential user base but also positions Samsung as a platform provider rather than a closed ecosystem, encouraging partnerships with other OEMs and reinforcing the value proposition of its software services.

For the industry, Hearapy signals a growing convergence of wellness and consumer audio. If adoption scales, we could see new revenue streams from premium health‑focused features, data‑driven personalization, and even insurance collaborations. Regulators may soon evaluate such therapeutic claims, prompting clearer guidelines. Nonetheless, the app’s free distribution lowers entry barriers, allowing Samsung to gather usage data and iterate quickly, potentially shaping the next wave of ear‑centric health innovations.